Charles K Gayer bought BCRX once, on May 13, 2024

Charles K. Gayer is a biopharmaceutical executive and corporate insider who serves as President and Chief Executive Officer of BioCryst Pharmaceuticals Inc. (BCRX), having previously held the role of Chief Commercial Officer and President & Chief Commercial Officer.( He joined BioCryst in 2015 as vice president of global strategic marketing, was promoted to Chief Commercial Officer in January 2020, and has been a key architect of the commercial strategy and launch operations for ORLADEYO (berotralstat), BioCryst’s oral kallikrein inhibitor for hereditary angioedema.( As CCO and later President, he built and led the commercial organization responsible for ORLADEYO’s global launch and revenue growth, and he has been reported as a significant equity holder and compensated executive of the company.(

Before joining BioCryst, Gayer held U.S. and global commercial leadership roles in rare disease-focused businesses at Talecris Biotherapeutics and Grifols, including responsibilities for alpha-1 antitrypsin deficiency marketing, European sales and marketing, and the combined immune globulin portfolio after Grifols acquired Talecris.( He previously spent six years in marketing and sales roles at GlaxoSmithKline, and began his career as a strategic consultant for biopharmaceutical companies, including three years as a business analyst at Genzyme Corporation.( Gayer holds a B.A. in Politics from Princeton University and an M.B.A. from Duke University’s Fuqua School of Business, reflecting a combination of policy, marketing, and business training that underpins his leadership in commercializing rare disease therapies.(

Written by Perplexity from public sources.